| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41581-018-0074-7 |
| P698 | PubMed publication ID | 30443016 |
| P50 | author | Claudia Mauri | Q60317802 |
| Kristine Oleinika | Q64497045 | ||
| P2093 | author name string | Alan D Salama | |
| P2860 | cites work | Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6 | Q24317429 |
| Rituximab: mechanism of action | Q24607358 | ||
| The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus | Q26799449 | ||
| Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity | Q26863295 | ||
| Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells | Q70067993 | ||
| In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis | Q70616889 | ||
| Reciprocal regulation of polarized cytokine production by effector B and T cells | Q73256871 | ||
| Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases | Q73880342 | ||
| B and T cell tolerance and autoimmunity in autoantibody transgenic mice | Q74535860 | ||
| Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation | Q77704355 | ||
| Up-regulation of interleukin-4 and CD23/FcepsilonRII in minimal change nephrotic syndrome | Q77827109 | ||
| Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production | Q78409883 | ||
| B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection | Q79370183 | ||
| A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus | Q80257443 | ||
| Neonatal lupus erythematosus | Q80282192 | ||
| Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy | Q80974156 | ||
| Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis | Q81402177 | ||
| Rituximab treatment of fibrillary glomerulonephritis | Q82109055 | ||
| B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit | Q82807525 | ||
| Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model | Q83374824 | ||
| Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome | Q83749717 | ||
| B cell abnormalities in Wegener's granulomatosis and microscopic polyangiitis: role of CD25+-expressing B cells | Q84754881 | ||
| Transitional B lymphocytes are associated with protection from kidney allograft rejection: a prospective study | Q86992487 | ||
| Altered B cell balance, but unaffected B cell capacity to limit monocyte activation in anti-neutrophil cytoplasmic antibody-associated vasculitis in remission | Q87675964 | ||
| Rituximab and B-cell return in ANCA-associated vasculitis | Q87938800 | ||
| CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas | Q89237299 | ||
| Bortezomib-based antibody depletion for refractory autoimmune hematological diseases | Q89776747 | ||
| Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis | Q89933799 | ||
| CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients | Q90681095 | ||
| Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production | Q35345421 | ||
| Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. | Q35662018 | ||
| The contribution of B cells to renal interstitial inflammation | Q35750182 | ||
| Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis | Q35835724 | ||
| Identification and characterization of circulating human transitional B cells | Q35847513 | ||
| Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients | Q35857405 | ||
| Autoregulatory function of interleukin-10-producing pre-naïve B cells is defective in systemic lupus erythematosus | Q35889002 | ||
| B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells | Q35946128 | ||
| Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis. | Q35946429 | ||
| IL-10-Producing Regulatory B Cells Are Decreased in Patients with Common Variable Immunodeficiency | Q35962914 | ||
| Renal Transplant Recipients Treated with Calcineurin-Inhibitors Lack Circulating Immature Transitional CD19+CD24hiCD38hi Regulatory B-Lymphocytes | Q35979565 | ||
| Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial | Q35993027 | ||
| Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells | Q36081961 | ||
| Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. | Q36085011 | ||
| Tolerant Kidney Transplant Patients Produce B Cells with Regulatory Properties | Q36104784 | ||
| B cell-associated immune profiles in patients with end-stage renal disease (ESRD) | Q36195585 | ||
| Antibody-mediated organ-allograft rejection | Q36263023 | ||
| Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials | Q36302240 | ||
| Successful T cell priming in B cell-deficient mice | Q36365741 | ||
| A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus | Q36369955 | ||
| Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. | Q36385029 | ||
| IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury | Q36417907 | ||
| Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab. | Q36652772 | ||
| Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice | Q36693339 | ||
| A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus | Q36718239 | ||
| B-cell targeting: a novel approach to immune intervention today and tomorrow | Q36922233 | ||
| Adenosine production by human B cells and B cell-mediated suppression of activated T cells | Q36983750 | ||
| Chronic alloantibody mediated rejection | Q37058050 | ||
| Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. | Q37109070 | ||
| Cytokine-producing effector B cells regulate type 2 immunity to H. polygyrus. | Q37349889 | ||
| Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses | Q37394650 | ||
| Regulatory B cells and tolerance in transplantation: from animal models to human. | Q37420774 | ||
| Rituximab for the treatment of rheumatoid arthritis: an update | Q37444678 | ||
| Biomarkers of Tolerance in Kidney Transplantation: Are We Predicting Tolerance or Response to Immunosuppressive Treatment? | Q37462039 | ||
| Rituximab in renal transplantation | Q27026434 | ||
| Predictors of disease relapse in IgG4-related disease following rituximab | Q27970306 | ||
| Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis | Q29619713 | ||
| Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates | Q30090232 | ||
| Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis | Q30541740 | ||
| B cells as antigen presenting cells | Q33238071 | ||
| B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells | Q33404838 | ||
| B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients | Q33706447 | ||
| Interleukin-35 induces regulatory B cells that suppress autoimmune disease. | Q33721777 | ||
| Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis | Q33740847 | ||
| Immunologic human renal allograft injury associates with an altered IL-10/TNF-α expression ratio in regulatory B cells | Q33814904 | ||
| B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjögren's syndrome: the similarities and differences | Q33822678 | ||
| Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies | Q33853373 | ||
| Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans | Q33882838 | ||
| Identification of a B cell signature associated with renal transplant tolerance in humans. | Q33882845 | ||
| Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries | Q33899815 | ||
| B cell-driven lymphangiogenesis in inflamed lymph nodes enhances dendritic cell mobilization | Q33993521 | ||
| Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis | Q34056484 | ||
| Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice | Q34083166 | ||
| B-cell-depleting induction therapy and acute cellular rejection | Q34085081 | ||
| CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients | Q34093165 | ||
| Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. | Q34144779 | ||
| B cells regulate autoimmunity by provision of IL-10. | Q34150590 | ||
| Prevention of arthritis by interleukin 10-producing B cells | Q34178104 | ||
| Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 | ||
| IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses | Q34330562 | ||
| IgG subclasses and allotypes: from structure to effector functions | Q34368678 | ||
| Human T-follicular helper and T-follicular regulatory cell maintenance is independent of germinal centers | Q34398374 | ||
| Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations | Q34419596 | ||
| Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation | Q34587471 | ||
| IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases | Q34658996 | ||
| Rituximab versus cyclophosphamide for ANCA-associated vasculitis | Q35109118 | ||
| Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-γ production by Th1 cells. | Q37601515 | ||
| B cells mediate chronic allograft rejection independently of antibody production | Q37602189 | ||
| Correlates of protection induced by vaccination | Q37750121 | ||
| Mechanism of regulation of autoimmunity by iNKT cells | Q37824008 | ||
| Immune regulatory function of B cells. | Q37973774 | ||
| B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design | Q38097129 | ||
| Rituximab biosimilars | Q38100232 | ||
| Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis | Q38408710 | ||
| Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study | Q38466691 | ||
| Antibody-independent functions of B cells: a focus on cytokines | Q38525103 | ||
| Monoclonal antibodies - A new era in the treatment of multiple myeloma. | Q38585300 | ||
| EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection | Q38692559 | ||
| Germinal Center B Cell Dynamics | Q38960786 | ||
| Human regulatory B cells in health and disease: therapeutic potential. | Q39156034 | ||
| A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo | Q39477266 | ||
| ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process | Q39486319 | ||
| The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model | Q39604863 | ||
| Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. | Q39648546 | ||
| Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients | Q39719491 | ||
| Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis. | Q40110864 | ||
| Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy | Q40208466 | ||
| Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis | Q40301437 | ||
| Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy | Q40404169 | ||
| Decreased IL-10(+) regulatory B cells (Bregs) in lupus nephritis patients | Q40765617 | ||
| Calcineurin and mTOR inhibitors have opposing effects on regulatory T cells while reducing regulatory B cell populations in kidney transplant recipients. | Q40808597 | ||
| Immunological memory and protective immunity: understanding their relation | Q40969823 | ||
| B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome | Q41124267 | ||
| Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. | Q41564823 | ||
| Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis | Q41676109 | ||
| Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation | Q41718326 | ||
| Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs | Q42025672 | ||
| B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells. | Q42221525 | ||
| Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus | Q42652135 | ||
| Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine. | Q42657479 | ||
| Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice | Q42721429 | ||
| CD4+ T cell activation and tolerance induction in B cell knockout mice | Q42943396 | ||
| Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis | Q42963758 | ||
| CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation | Q43406136 | ||
| Anti-glomerular basement membrane antibody-induced glomerulonephritis | Q44843595 | ||
| Repeat protocol renal biopsy in ANCA-associated renal vasculitis | Q44936070 | ||
| Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells | Q44996678 | ||
| A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. | Q45304143 | ||
| Regulatory B cells in ANCA-associated vasculitis. | Q45840349 | ||
| TLR-activated B cells suppress T cell-mediated autoimmunity | Q46434575 | ||
| A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction | Q46606282 | ||
| The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production | Q46938631 | ||
| Transcriptional profiling of PBMCs unravels B cell mediated immunopathogenic imprints of HCV vasculitis | Q47171530 | ||
| A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection | Q47292306 | ||
| Abnormal B-cell development in Systemic Lupus Erythematosus: what the genetics tell us. | Q47365066 | ||
| B cell-derived IL-4 acts on podocytes to induce proteinuria and foot process effacement. | Q47384287 | ||
| Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Schönlein). | Q47705620 | ||
| Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help | Q47800822 | ||
| Prospective Analyses of Circulating B Cell Subsets in ABO-Compatible and ABO-Incompatible Kidney Transplant Recipients. | Q48109603 | ||
| CD1d-dependent immune suppression mediated by regulatory B cells through modulations of iNKT cells. | Q49959102 | ||
| B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. | Q50591666 | ||
| IL-10-producing regulatory B cells are decreased in patients with psoriasis. | Q50692067 | ||
| Natural killer T cells in families of patients with systemic lupus erythematosus: their possible role in regulation of IGG production. | Q50703276 | ||
| Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission. | Q50786110 | ||
| Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease. | Q50850119 | ||
| An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. | Q50963419 | ||
| Influence of drug molecules on regulatory B cells. | Q51025438 | ||
| The role of regulatory B cells (Bregs) in the Tregs-amplifying effect of Sirolimus. | Q51722347 | ||
| Minimal Change Disease. | Q52945061 | ||
| Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. | Q53200046 | ||
| Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. | Q53256514 | ||
| Numerical and functional deficiencies of natural killer T cells in systemic lupus erythematosus: their deficiency related to disease activity. | Q53440459 | ||
| Relapsed Wegener's granulomatosis after rituximab therapy--B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood. | Q53469323 | ||
| Systemic lupus erythematosus. | Q53495545 | ||
| CD20+ lymphocytes in renal allografts are associated with poor graft survival in pediatric patients. | Q53580038 | ||
| B-Cells induce regulatory T cells through TGF-β/IDO production in A CTLA-4 dependent manner. | Q53584724 | ||
| Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. | Q53924174 | ||
| Functional implications of regulatory B cells in human IgA nephropathy | Q56767513 | ||
| Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents | Q56896719 | ||
| TLR-mediated STAT3 and ERK activation controls IL-10 secretion by human B cells | Q58234774 | ||
| A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis | Q58377805 | ||
| Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies | Q60962707 | ||
| P433 | issue | 1 | |
| P921 | main subject | kidney disease | Q1054718 |
| P304 | page(s) | 11-26 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Nature Reviews Nephrology | Q2079275 |
| P1476 | title | Effector and regulatory B cells in immune-mediated kidney disease | |
| P478 | volume | 15 |
| Q98778531 | ANCA-associated vasculitis |
| Q91975364 | Circulating Lymphocyte Subsets Induce Secondary Infection in Acute Pancreatitis |
| Q92097039 | Design and application of single-cell RNA sequencing to study kidney immune cells in lupus nephritis |
| Q99608040 | Global proteome and phosphoproteome characterization of sepsis-induced kidney injury |
| Q99711021 | Immune cell composition in normal human kidneys |
| Q91844402 | Peripheral B Cell Subsets in Autoimmune Diseases: Clinical Implications and Effects of B Cell-Targeted Therapies |
| Q96306728 | Transcriptional meta-analysis of regulatory B cells |
| Q90403326 | Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases |
Search more.